[theold]

It’s a boost for Novavax, which has suffered months of delays after manufacturing problems despite securing some of the largest funding from the Trump administration in the early stages of the pandemic.

There’s limited data on the effectiveness of Nuvaxovid against omicron, according to the European regulator.

“An authorization from the commission would deliver the first protein-based vaccine to the EU during a critical time when we believe having choice among vaccines will lead to increased immunization,” Stanley Erck, Novavax’s chief executive officer, wrote in the statement.


https://www.bloomberg.com/news/articles/...-of-delays